Drugs / GSK690693
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00666081 | Apr 2008 → Dec 2009 | cancer | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00493818 | Apr 2007 → Jun 2008 | cancer | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK690693 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00666081 ↗ |
| Action | Inhibit | “AKT inhibitor GSK690693” NCT00493818 ↗ |
| Modality | Small molecule | — CHEMBL494089 ↗ |
| Route | Intravenous | “Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.” NCT00666081 ↗ |